1. Home
  2. IONR vs OMER Comparison

IONR vs OMER Comparison

Compare IONR & OMER Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • IONR
  • OMER
  • Stock Information
  • Founded
  • IONR 2001
  • OMER 1994
  • Country
  • IONR Australia
  • OMER United States
  • Employees
  • IONR N/A
  • OMER N/A
  • Industry
  • IONR
  • OMER Biotechnology: Pharmaceutical Preparations
  • Sector
  • IONR
  • OMER Health Care
  • Exchange
  • IONR Nasdaq
  • OMER Nasdaq
  • Market Cap
  • IONR 397.5M
  • OMER 391.1M
  • IPO Year
  • IONR N/A
  • OMER 2009
  • Fundamental
  • Price
  • IONR $5.05
  • OMER $6.75
  • Analyst Decision
  • IONR
  • OMER Buy
  • Analyst Count
  • IONR 0
  • OMER 3
  • Target Price
  • IONR N/A
  • OMER $9.00
  • AVG Volume (30 Days)
  • IONR 65.6K
  • OMER 1.0M
  • Earning Date
  • IONR 01-01-0001
  • OMER 11-13-2024
  • Dividend Yield
  • IONR N/A
  • OMER N/A
  • EPS Growth
  • IONR N/A
  • OMER N/A
  • EPS
  • IONR N/A
  • OMER N/A
  • Revenue
  • IONR N/A
  • OMER N/A
  • Revenue This Year
  • IONR N/A
  • OMER N/A
  • Revenue Next Year
  • IONR N/A
  • OMER N/A
  • P/E Ratio
  • IONR N/A
  • OMER N/A
  • Revenue Growth
  • IONR N/A
  • OMER N/A
  • 52 Week Low
  • IONR $2.90
  • OMER $1.49
  • 52 Week High
  • IONR $9.35
  • OMER $7.51
  • Technical
  • Relative Strength Index (RSI)
  • IONR 33.42
  • OMER 80.62
  • Support Level
  • IONR $5.66
  • OMER $4.18
  • Resistance Level
  • IONR $5.99
  • OMER $7.51
  • Average True Range (ATR)
  • IONR 0.48
  • OMER 0.43
  • MACD
  • IONR -0.30
  • OMER 0.24
  • Stochastic Oscillator
  • IONR 0.82
  • OMER 78.29

About IONR ioneer Ltd

Ioneer Ltd is a mineral exploration company. The company's focus is on the Rhyolite Ridge Lithium-Boron Project located in Nevada, USA. Geographically, the group has a business presence in Australia and North America. The company's focus is to develop a U.S.-based source of lithium and boron that can be extracted in an environmentally and socially responsible manner, providing two materials that are essential to achieve a sustainable future for the planet.

About OMER Omeros Corporation

Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The lead drug candidate in the pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy.

Share on Social Networks: